Clinical Features and Antimicrobial Susceptibility of Pseudomonas aeruginosa and Acinetobacter baumannii Complex Isolates in Intensive Care Patients with Chronic Obstructive Pulmonary Disease and Community-Acquired Pneumonia in Taiwan

References

• Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2021.
   Web of Science ®Google Scholar
• Soriano JB, Visick GT, Muellerova H, Payvandi N, Hansell AL. Patterns of comorbidities in newly diagnosed COPD and asthma in primary care. Chest. 2005;128(4):2099–2107. doi:10.1378/chest.128.4.2099
   PubMed Web of Science ®Google Scholar
• Müllerova H, Chigbo C, Hagan GW, et al. The natural history of community-acquired pneumonia in COPD patients: a population database analysis. Respir Med. 2012;106(8):1124–1133.
   PubMed Web of Science ®Google Scholar
• Fine MJ, Smith MA, Carson CA, et al. Prognosis and outcomes of patients with community-acquired pneumonia: a meta-analysis. JAMA. 1996;275(2):134–141.
   PubMed Web of Science ®Google Scholar
• Restrepo MI, Mortensen EM, Pugh JA, Anzueto A. COPD is associated with increased mortality in patients with community-acquired pneumonia. Eur Respir J. 2006;28(2):346–351.
   PubMed Web of Science ®Google Scholar
• Musher DM, Thorner AR. Community-acquired pneumonia. N Engl J Med. 2014;371(17):1619–1628.
   PubMed Web of Science ®Google Scholar
• Cilli A, Erdem H, Karakurt Z, et al. Community-acquired pneumonia in patients with chronic obstructive pulmonary disease requiring admission to the intensive care unit: risk factors for mortality. J Crit Care. 2013;28(6):975–979.
   PubMed Web of Science ®Google Scholar
• Ko FW, Ip M, Chan PK, Ng SS, Chau S, Hui DS. A one-year prospective study of infectious etiology in patients hospitalized with acute exacerbations of COPD and concomitant pneumonia. Respir Med. 2008;102(8):1109–1116.
   PubMed Web of Science ®Google Scholar
• Pifarre R, Falguera M, Vicente-de-vera C, Nogues A. Characteristics of community-acquired pneumonia in patients with chronic obstructive pulmonary disease. Respir Med. 2007;101(10):2139–2144.
   PubMed Web of Science ®Google Scholar
• Huang WC, Lee CH, Wu MF, et al. Clinical features, bacteriology of endotracheal aspirates and treatment outcomes of patients with chronic obstructive pulmonary disease and community-acquired pneumonia in an intensive care unit in Taiwan with an emphasis on eosinophilia versus non-eosinophilia: a retrospective case–control study. BMJ Open. 2018;8(9):e020341.
   PubMed Web of Science ®Google Scholar
• Eklöf J, Sørensen R, Ingebrigtsen T, et al. Pseudomonas aeruginosa and risk of death and exacerbations in patients with chronic obstructive pulmonary disease: an observational cohort study of 22 053 patients. Clin Microbiol Infect. 2020;26(2):227–234.
   PubMed Web of Science ®Google Scholar
• Chung DR, Song JH, Kim SH, et al. High prevalence of multidrug-resistant nonfermenters in hospital-acquired pneumonia in Asia. Am J Respir Crit Care Med. 2011;184(12):1409–1417. doi:10.1164/rccm.201102-0349OC
   PubMed Web of Science ®Google Scholar
• Huang WC, Wu MF, Huang CC, et al. Dynamics of the lung microbiome in intensive care patients with chronic obstructive pulmonary disease and community-acquired pneumonia. Sci Rep. 2020;10(1):1–10.
   PubMed Web of Science ®Google Scholar
• Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2017.
   Web of Science ®Google Scholar
• Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis. 2007;44 Suppl 2(Suppl 2):S27–72. doi:10.1086/511159
   PubMedGoogle Scholar
• Leung WS, Chu CM, Tsang KY, Lo FH, Lo KF, Ho PL. Fulminant community-acquired Acinetobacter baumannii pneumonia as a distinct clinical syndrome. Chest. 2006;129(1):102–109. doi:10.1378/chest.129.1.102
   PubMed Web of Science ®Google Scholar
• American Thoracic Society. Lung function testing: selection of reference values and interpretative strategies. Am Rev Respir Dis. 1991;144(5):1202–1218. doi:10.1164/ajrccm/144.5.1202.
   PubMed Web of Science ®Google Scholar
• Fine MJ, Hanusa BH, Lave JR, et al. Comparison of a disease-specific and a generic severity of illness measure for patients with community-acquired pneumonia. J Gen Intern Med. 1995;10(7):359–368. doi:10.1007/bf02599830
   PubMed Web of Science ®Google Scholar
• Standards. NCfCL. Performance Standards for Antimicrobial Susceptibility Testing. 12th Informational Supplement. Approved Standard M100-S12. Wayne: National Committee for Clinical Laboratory Standards; 2002.
   Google Scholar
• Eller J, Ede A, Schaberg T, Niederman MS, Mauch H, Lode H. Infective exacerbations of chronic bronchitis: relation between bacteriologic etiology and lung function. Chest. 1998;113(6):1542–1548.
   PubMed Web of Science ®Google Scholar
• Miravitlles M, Espinosa C, Fernández-Laso E, Martos JA, Maldonado JA, Gallego M. Relationship between bacterial flora in sputum and functional impairment in patients with acute exacerbations of COPD. Chest. 1999;116(1):40–46.
   PubMed Web of Science ®Google Scholar
• Groenewegen KH, Wouters EF. Bacterial infections in patients requiring admission for an acute exacerbation of COPD; a 1-year prospective study. Respir Med. 2003;97(7):770–777.
   PubMed Web of Science ®Google Scholar
• Garcia-Vidal C, Almagro P, Romaní V, et al. Pseudomonas aeruginosa in patients hospitalised for COPD exacerbation: a prospective study. Eur Respir J. 2009;34(5):1072–1078.
   PubMed Web of Science ®Google Scholar
• Parameswaran GI, Sethi S. Pseudomonas infection in chronic obstructive pulmonary disease. Future Microbiol. 2012;7(10):1129–1132.
   PubMed Web of Science ®Google Scholar
• Gallego M, Pomares X, Espasa M, et al. Pseudomonas aeruginosa isolates in severe chronic obstructive pulmonary disease: characterization and risk factors. BMC Pulm Med. 2014;14(1):1–12.
   PubMedGoogle Scholar
• Boixeda R, Almagro P, Díez-Manglano J, et al. Bacterial flora in the sputum and comorbidity in patients with acute exacerbations of COPD. Int J Chron Obstruct Pulmon Dis. 2015;10:2581.
   PubMedGoogle Scholar
• Celli BR, Cote CG, Marin JM, et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med. 2004;350(10):1005–1012.
   PubMed Web of Science ®Google Scholar
• Peng C, Zong Z, Fan H. Acinetobacter baumannii isolates associated with community-acquired pneumonia in West China. Clin Microbiol Infect. 2012;18(12):E491–E493.
   PubMed Web of Science ®Google Scholar
• Wang YC, Lee YT, Yang YS, et al. Risk factors and outcome for colistin-resistant Acinetobacter nosocomialis bacteraemia in patients without previous colistin exposure. Clin Microbiol Infect. 2015;21(8):758–764.
   PubMed Web of Science ®Google Scholar
• Li YJ, Pan CZ, Fang CQ, et al. Pneumonia caused by extensive drug-resistant Acinetobacter baumannii among hospitalized patients: genetic relationships, risk factors and mortality. BMC Infect Dis. 2017;17(1):371. doi:10.1186/s12879-017-2471-0
   PubMedGoogle Scholar
• Özgür ES, Horasan ES, Karaca K, Ersöz G, Atış SN, Kaya A. Ventilator-associated pneumonia due to extensive drug-resistant Acinetobacter baumannii: risk factors, clinical features, and outcomes. Am J Infect Control. 2014;42(2):206–208.
   PubMed Web of Science ®Google Scholar
• Restrepo MI, Babu BL, Reyes LF, et al. Burden and risk factors for Pseudomonas aeruginosa community-acquired pneumonia: a multinational point prevalence study of hospitalised patients. Eur Respir J. 2018;52:2.
   Web of Science ®Google Scholar
• Weiner LM, Webb AK, Limbago B, et al. Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2011–2014. Infect Control Hosp Epidemiol. 2016;37(11):1288–1301.
   PubMed Web of Science ®Google Scholar
• Jernigan JA, Hatfield KM, Wolford H, et al. Multidrug-resistant bacterial infections in U.S. Hospitalized patients, 2012-2017. N Engl J Med. 2020;382(14):1309–1319. doi:10.1056/NEJMoa1914433
   PubMed Web of Science ®Google Scholar
• Chen LK, Kuo SC, Chang KC, et al. Clinical antibiotic-resistant Acinetobacter baumannii strains with higher susceptibility to environmental phages than antibiotic-sensitive strains. Sci Rep. 2017;7(1):6319. doi:10.1038/s41598-017-06688-w
   PubMedGoogle Scholar
• Chuang YC, Cheng CY, Sheng WH, et al. Effectiveness of tigecycline-based versus colistin- based therapy for treatment of pneumonia caused by multidrug-resistant Acinetobacter baumannii in a critical setting: a matched cohort analysis. BMC Infect Dis. 2014;14:102. doi:10.1186/1471-2334-14-102
   PubMed Web of Science ®Google Scholar
• Fujitani S, Sun HY, Yu VL, Weingarten JA. Pneumonia due to Pseudomonas aeruginosa: part I: epidemiology, clinical diagnosis, and source. Chest. 2011;139(4):909–919. doi:10.1378/chest.10-0166
   PubMed Web of Science ®Google Scholar
• Eklöf J, Sørensen R, Ingebrigtsen TS, et al. Pseudomonas aeruginosa and risk of death and exacerbations in patients with chronic obstructive pulmonary disease: an observational cohort study of 22 053 patients. Clin Microbiol Infect. 2020;26(2):227–234. doi:10.1016/j.cmi.2019.06.011
   PubMed Web of Science ®Google Scholar
• Tumbarello M, De Pascale G, Trecarichi EM, et al. Clinical outcomes of Pseudomonas aeruginosa pneumonia in intensive care unit patients. Intensive Care Med. 2013;39(4):682–692. doi:10.1007/s00134-013-2828-9
   PubMed Web of Science ®Google Scholar
• Vedel-Krogh S, Nielsen SF, Lange P, Vestbo J, Nordestgaard BG. Blood Eosinophils and Exacerbations in Chronic Obstructive Pulmonary Disease. The Copenhagen General Population Study. Am J Respir Crit Care Med. 2016;193(9):965–974. doi:10.1164/rccm.201509-1869OC
   PubMed Web of Science ®Google Scholar
• David B, Bafadhel M, Koenderman L, De Soyza A. Eosinophilic inflammation in COPD: from an inflammatory marker to a treatable trait. Thorax. 2020;76(2):188–195. doi:10.1136/thoraxjnl-2020-215167
   PubMed Web of Science ®Google Scholar
• Wedzicha JA. Eosinophils as Biomarkers of Chronic Obstructive Pulmonary Disease Exacerbation Risk. Maybe Just for Some? Am J Respir Crit Care Med. 2016;193(9):937–938. doi:10.1164/rccm.201601-0015ED
   PubMed Web of Science ®Google Scholar